Competitor Analysis: Targeted Therapy of Obesity
The present Competitive Intelligence Report about Targeted Therapy of Obesity provides a competitor evaluation in the field of novel molecules being developed for treatment of obesity as of March 2011. Pharmacologic approaches include reduction of energy uptake from the GI and Genitourinary tract, reduction of food consumption via peripheral mechanisms as well as via signalling to the brain from the GI tract, action in the CNS and reduction of fat mass & regulation of energy metabolism. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Obesity is a serious and worldwide health problem because it is a major risk factor for metabolic syndrome including pre-diabetes, hypertension and other cardiovascular (CV) and non-CV complications. Pharmacotherapeutic options so far are limited in their effect or even have been withdrawn from market due to neuropsychological side effects. Despite many study failure, the clinical pipeline consists of more than 43 different molecular entities with four drugs in pre-registration of registration phases. Molecular strategies in R&D include intentions to lower body weight or adipose tissue mass by reducing the absorption of lipids from the GI tract, to limit food intake, or to increase energy expenditure or to reduce adipose tissue size. The majority (74%) of the new molecular entities (NME) in development for treatment of obesity are small molecules, and about 18 % of the NMEs are anti-obesity peptides.
The report includes a compilation of currently active projects in clinical research and development of antisense, aptamer, LNA RNA, RNAi and CpG oligonucleotide therapeutics for treatment of a variety of clinical disorders. In addition, the report lists company-specific R&D pipelines of RNA Therapeutics in Clinical Develompent. Competitor projects are listed in a tabular format providing information on:
Index
1) Reduction of Energy Uptake from the GI and Genitourinary Tract
a) Inhibitors of Panreatic Lipase
b) Inhibitors of Intestinal Microsomal Trigliceride Transfer Protein (MTP)
c) Inhibitors of Acyl-CoA:diacyl-glycerol acyltransfe-rase 1(DGAT1)
d) Inhibitors of Low-Affinity Sodium-Dependent Glucose Co-transporters (SGLT2)
e) Others
2) Reduction of Food Consumption via Peripheral Mechanisms
a) Cannabinoid 1 (CB1) receptor antagonist
b) GPR119 agonists
c) Opioid Receptors
d) PPAR Agonists
e) Antagonists of Glucocorticoid Receptor (GCCR)
f) Others
3) Reduction of Food Consumption via Signalling to the Brain from the GI Tract
a) Amylin & Leptin Analogues
b) Peptide YY (PYY) & Pancreatic Polypeptide (PP) Analogues
3c) GLP-1 & Oxyntomodulin Analogues
d) Cholecystokinin (CCK) Agonists
e) Ghrelin Receptor Antagonists
f) Others
4) Centrally Acting Drugs
a) Compounds Predominantly Modulating Local Availability of Dopamine, Norepinephrine and Serotonin in the Brain
b) MC4R (Melanocortin 4 Receptor) Agonists and MCH-R1 (Melanin-Concentrating Hormone Receptor 1) Antagonists
c) H3 Receptor Antagonists
d) Neuropeptide Y (NPY) Receptor Antagonists & Agouti-Related Protein (AgRP) Inhibitors
5) Reduction of Fat Mass & Regulation of Energy Metabolism
a) Growth Hormone (GH) Analogues
b) 11beta-Hydroxysteroid Dehydrogenase type 1 (11beta-HSD1) Inhibitors
c) Angiogenesis Inhibitors
d) TGR5 Agonists
e) Methionine aminopeptidase 2 (MetAP2) Inhibitors
f) Other Metabolic Modifiers
6) Various Approaches
7) Unspecified Targets
Corporate Targeted Therapy of Obesity R&D Pipelines
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Obesity is a serious and worldwide health problem because it is a major risk factor for metabolic syndrome including pre-diabetes, hypertension and other cardiovascular (CV) and non-CV complications. Pharmacotherapeutic options so far are limited in their effect or even have been withdrawn from market due to neuropsychological side effects. Despite many study failure, the clinical pipeline consists of more than 43 different molecular entities with four drugs in pre-registration of registration phases. Molecular strategies in R&D include intentions to lower body weight or adipose tissue mass by reducing the absorption of lipids from the GI tract, to limit food intake, or to increase energy expenditure or to reduce adipose tissue size. The majority (74%) of the new molecular entities (NME) in development for treatment of obesity are small molecules, and about 18 % of the NMEs are anti-obesity peptides.
The report includes a compilation of currently active projects in clinical research and development of antisense, aptamer, LNA RNA, RNAi and CpG oligonucleotide therapeutics for treatment of a variety of clinical disorders. In addition, the report lists company-specific R&D pipelines of RNA Therapeutics in Clinical Develompent. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
1) Reduction of Energy Uptake from the GI and Genitourinary Tract
a) Inhibitors of Panreatic Lipase
b) Inhibitors of Intestinal Microsomal Trigliceride Transfer Protein (MTP)
c) Inhibitors of Acyl-CoA:diacyl-glycerol acyltransfe-rase 1(DGAT1)
d) Inhibitors of Low-Affinity Sodium-Dependent Glucose Co-transporters (SGLT2)
e) Others
2) Reduction of Food Consumption via Peripheral Mechanisms
a) Cannabinoid 1 (CB1) receptor antagonist
b) GPR119 agonists
c) Opioid Receptors
d) PPAR Agonists
e) Antagonists of Glucocorticoid Receptor (GCCR)
f) Others
3) Reduction of Food Consumption via Signalling to the Brain from the GI Tract
a) Amylin & Leptin Analogues
b) Peptide YY (PYY) & Pancreatic Polypeptide (PP) Analogues
3c) GLP-1 & Oxyntomodulin Analogues
d) Cholecystokinin (CCK) Agonists
e) Ghrelin Receptor Antagonists
f) Others
4) Centrally Acting Drugs
a) Compounds Predominantly Modulating Local Availability of Dopamine, Norepinephrine and Serotonin in the Brain
b) MC4R (Melanocortin 4 Receptor) Agonists and MCH-R1 (Melanin-Concentrating Hormone Receptor 1) Antagonists
c) H3 Receptor Antagonists
d) Neuropeptide Y (NPY) Receptor Antagonists & Agouti-Related Protein (AgRP) Inhibitors
5) Reduction of Fat Mass & Regulation of Energy Metabolism
a) Growth Hormone (GH) Analogues
b) 11beta-Hydroxysteroid Dehydrogenase type 1 (11beta-HSD1) Inhibitors
c) Angiogenesis Inhibitors
d) TGR5 Agonists
e) Methionine aminopeptidase 2 (MetAP2) Inhibitors
f) Other Metabolic Modifiers
6) Various Approaches
7) Unspecified Targets
Corporate Targeted Therapy of Obesity R&D Pipelines
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
